C. and I. ,

, Massachusetts General Hospital

I. and U. , Service d'Oncologie Médicale Thoracique et Digestive, Hôpital Laënnec, INSERM U1019, CIIL Institut Pasteur de, p.59000

C. Lille and . Lille, Avenue Oscar Lambret, F-59000 Lille, France. 9 Laboratory of Clinical and Experimental Pathology and Hospital-related Biobank, Chirurgie Thoracique et Transplantation pulmonaire

N. J. Vogelzang, J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel et al., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma, J Clin Oncol, vol.21, pp.2636-2680, 2003.

H. H. Sun, A. Vaynblat, and H. I. Pass, Diagnosis and prognosis-review of biomarkers for mesothelioma, Ann Transl Med, vol.5, p.244, 2017.

F. Gueugnon, S. Leclercq, C. Blanquart, C. Sagan, L. Cellerin et al., Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011.

B. C. Duysinx, A. Paulus, V. Heinen, D. Nguyen, M. Henket et al., Diagnostic value of neurotrophin expression in malignant pleural effusions, Exp Ther Med, vol.2, pp.941-947, 2011.

W. A. Nockher and H. Renz, Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation, Clin Chim Acta, vol.352, pp.49-74, 2005.

I. Pantazopoulos, P. Boura, T. Xanthos, and K. Syrigos, Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma, Eur Respir J, vol.41, pp.706-721, 2013.

A. Ricci, S. Mariotta, E. Pompili, R. Mancini, E. Bronzetti et al., Neurotrophin system activation in pleural effusions, Growth Factors, vol.28, pp.221-252, 2010.

D. P. Radin and P. Patel, BDNF: an oncogene or tumor suppressor?, Anticancer Res, vol.37, pp.3983-90, 2017.

A. Tajbakhsh, A. Mokhtari-zaer, M. Rezaee, F. Afzaljavan, M. Rivandi et al., Therapeutic potentials of BDNF/TrkB in breast Cancer; current status and perspectives, J Cell Biochem, vol.118, pp.2502-2517, 2017.

G. Zalcman, J. Mazieres, J. Margery, L. Greillier, C. Audigier-valette et al., Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin Pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, vol.387, pp.1405-1419, 2016.